人类细胞色素P-450（异喹胍/鹰爪豆碱型）在22号染色体上的染色体定位。
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.
作者信息
Eichelbaum M, Baur M P, Dengler H J, Osikowska-Evers B O, Tieves G, Zekorn C, Rittner C
出版信息
Br J Clin Pharmacol. 1987 Apr;23(4):455-8. doi: 10.1111/j.1365-2125.1987.tb03075.x.
Abstract
In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out. Positive information for linkage between PSO and the P1 blood group was obtained with a maximal LOD-score of LOD = 3.35 for both male and female recombination fraction estimates of theta m = theta f = 0.0. The P1 blood group has been recently mapped to the long arm of chromosome 22. Thus it can be concluded that the gene controlling human cytochrome P-450 (debrisoquine/sparteine) is situated on the long arm of chromosome 22 in close vicinity to P1.
摘要
为了确定控制人细胞色素P - 450（异喹胍/鹰爪豆碱型）的基因位于哪条染色体上，开展了多态性鹰爪豆碱氧化（PSO）与各种多态性标记的连锁研究。获得了PSO与P1血型之间连锁的阳性信息，男性和女性重组率估计值θm = θf = 0.0时，最大LOD值为LOD = 3.35。P1血型最近已被定位到22号染色体长臂上。因此可以得出结论，控制人细胞色素P - 450（异喹胍/鹰爪豆碱）的基因位于22号染色体长臂上，与P1紧密相邻。
相似文献
1
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.
Br J Clin Pharmacol. 1987 Apr;23(4):455-8. doi: 10.1111/j.1365-2125.1987.tb03075.x.
2
Polymorphic oxidation of debrisoquine and sparteine.
Prog Clin Biol Res. 1986;214:157-67.
3
4
Molecular genetics of the debrisoquin-sparteine polymorphism.
Clin Pharmacol Ther. 1991 Sep;50(3):233-8. doi: 10.1038/clpt.1991.131.
5
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
Pharmacogenetics. 1992 Apr;2(2):89-92. doi: 10.1097/00008571-199204000-00006.
6
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Can J Physiol Pharmacol. 1984 Jul;62(7):860-2. doi: 10.1139/y84-144.
7
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x.
8
Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Biochem Pharmacol. 1988 Oct 15;37(20):3829-35. doi: 10.1016/0006-2952(88)90063-9.
9
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
10
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
引用本文的文献
1
Relevance of Gene Variants in Population Genetic Differentiation.
Pharmaceutics. 2022 Nov 16;14(11):2481. doi: 10.3390/pharmaceutics14112481.
2
Pharmacogenetic factors affecting β-blocker metabolism and response.
Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):953-964. doi: 10.1080/17425255.2020.1803279. Epub 2020 Sep 9.
3
PharmVar GeneFocus: CYP2D6.
Clin Pharmacol Ther. 2020 Jan;107(1):154-170. doi: 10.1002/cpt.1643. Epub 2019 Dec 9.
4
Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Neurochem Res. 2017 Dec;42(12):3353-3361. doi: 10.1007/s11064-017-2384-8. Epub 2017 Sep 4.
5
Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.
Pharmacogenomics. 2017 May;18(7):673-685. doi: 10.2217/pgs-2017-0033. Epub 2017 May 4.
6
CYP2D6 polymorphisms and their influence on risperidone treatment.
Pharmgenomics Pers Med. 2016 Dec 1;9:131-147. doi: 10.2147/PGPM.S107772. eCollection 2016.
7
Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method.
Hum Genomics. 2016 Apr 23;10:11. doi: 10.1186/s40246-016-0073-3.
8
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000.
9
Cytochrome P450 2D6.
Pharmacogenet Genomics. 2009 Jul;19(7):559-62. doi: 10.1097/FPC.0b013e32832e0e97.
10
Management of postoperative nausea and vomiting: focus on palonosetron.
Ther Clin Risk Manag. 2009 Feb;5(1):21-34. Epub 2009 Mar 26.
本文引用的文献
1
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
2
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
3
Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible cytochrome P1-450 gene to chromosome 15.
Nucleic Acids Res. 1985 Mar 25;13(6):2009-16. doi: 10.1093/nar/13.6.2009.
4
Report of the Committee on the Genetic Constitution of Chromosomes 20, 21, and 22.
Cytogenet Cell Genet. 1985;40(1-4):268-95. doi: 10.1159/000132177.
5
The influence of enzyme induction on polymorphic sparteine oxidation.
Br J Clin Pharmacol. 1986 Jul;22(1):49-53. doi: 10.1111/j.1365-2125.1986.tb02879.x.
6
The genetic polymorphism of sparteine metabolism.
Xenobiotica. 1986 May;16(5):465-81. doi: 10.3109/00498258609050252.
7
Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.
Xenobiotica. 1986 May;16(5):367-78. doi: 10.3109/00498258609050245.
8
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
Eur J Clin Pharmacol. 1986;29(6):739-41. doi: 10.1007/BF00615971.
9
A cytochrome P-450 gene family mapped to human chromosome 19.
Ann Hum Genet. 1985 Oct;49(4):267-74. doi: 10.1111/j.1469-1809.1985.tb01702.x.
10
Molecular genetics of the fourth component of human complement and steroid 21-hydroxylase.
Immunol Rev. 1985 Oct;87:39-60. doi: 10.1111/j.1600-065x.1985.tb01144.x.
Zotero 插件